Clinical Research Directory
Browse clinical research sites, groups, and studies.
Accelerated ART Initiation for PWHIV Who Are Out of Care
Sponsor: University of Missouri-Columbia
Summary
The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24. The study will also assess the acceptability, appropriateness, feasibility, and sustainability of the ACCELERATE model of care. The ACCELERATE model combines a standardized method for outreach, the use of telehealth for rapid access to an HIV care provider, a simplified pre-approved HIV regimen, a free 30-day medication starter supply, and re-linkage to medical care.
Official title: ACCELERATE a Multisite Prospective Hybrid (Effectiveness-implementation) Type 2 Design, Single-arm, Mixed-methods Study of a Simplified Accelerated ART Initiation Protocol for People With HIV Who Are Out of Care.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-04-29
Completion Date
2026-11-01
Last Updated
2025-04-20
Healthy Volunteers
No
Conditions
Interventions
The Accelerate model of care
Contact is established by the study team The patient is provided with a telehealth appointment with an HIV care provider within 24 business hours of contact At the time of enrollment/initial clinic visit, patients who meet the inclusion and exclusion criteria will be enrolled in the study The HIV care provider will prescribe B/F/TAF to their pharmacy of choice. B/F/TAF is dispensed by the designated study pharmacist and mailed to the patient as a free 30-day starter pack to allow time for benefits verification. A telephone follow-up call by the study team will be conducted within 2 - 4 weeks from the initial clinical visit to assess any adverse events, tolerability, and adherence. Hand-off to HIV clinic to establish care within 4 weeks. Lab results will be drawn during clinic per HIV care provider which might include CBC, CMP, HIV-1 RNA, CD4, and genotype resistance testing when clinically indicated by the HIV care provider.
bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Same as above, it is the same intervetion
Locations (4)
University of Missouri-Columbia
Columbia, Missouri, United States
KC Care Health Center
Kansas City, Missouri, United States
AIDS Project of the Ozarks
Springfield, Missouri, United States
NOVUS Health
St Louis, Missouri, United States